✦ LIBER ✦

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

✍ Scribed by Mateos, M. V.; Richardson, P. G.; Schlag, R.; Khuageva, N. K.; Dimopoulos, M. A.; Shpilberg, O.; Kropff, M.; Spicka, I.; Petrucci, M. T.; Palumbo, A.

Book ID: 111922180
Publisher: American Society of Clinical Oncology
Year: 2010
Tongue: English
Weight: 493 KB
Volume: 28
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2009.26.0638

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fewer bone disease events, improvement i

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma

✍ Michel Delforge; Evangelos Terpos; Paul G. Richardson; Ofer Shpilberg; Nuriet K. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 364 KB

Bortezomib, melphalan, and prednisone ve

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

✍ María-Victoria Mateos; Albert Oriol; Joaquín Martínez-López; Norma Gutiérrez; An 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 255 KB

“Short Course” Bortezomib plus Melphalan

“Short Course” Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma

✍ Cristina Gasparetto; Jon P. Gockerman; Louis F. Diehl; Carlos M. de Castro; Jose 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 382 KB

Risk factors for, and reversibility of,

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

✍ Meletios A. Dimopoulos; Maria-Victoria Mateos; Paul G. Richardson; Rudolf Schlag 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB

PCN140 IMPACT OF TUMOR RESPONSE ON HEALT

PCN140 IMPACT OF TUMOR RESPONSE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH VELCADE/MELPHALAN/PREDNISONE (V-MP): RESULTS FROM THE VISTA TRIAL

✍ J Meunier; A Regnault; D Robinson; K Rosa; JF San Miguel; H van de Velde; PG Ric 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

Treatment of Bendamustine and Prednisone

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

✍ W. Pönisch; P. S. Mitrou; K. Merkle; M. Herold; M. Assmann; G. Wilhelm; K. Dachs 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 344 KB